Celularity (CELU) AI Stock Analysis

• Market Cap: $38.35M
• Dividend Yield: N/A
• Average Volume (3M): 206.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.50
• Revenue Growth: -15.81%
• EPS Growth: -113.06%
• Country: US
• Employees: 120
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.02
• Shares Outstanding: 28,837,788
• 10 Day Avg. Volume: 277,262
• 30 Day Avg. Volume: 206,824
• PEG Ratio: 0.01
• Price to Book (P/B): 5.15
• Price to Sales (P/S): 0.84
• P/FCF Ratio: -6.94
• Enterprise Value/Market Cap: 3.03
• Enterprise Value/Revenue: 2.87
• Enterprise Value/Gross Profit: 5.19
• Enterprise Value/Ebitda: -1.83
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $1.50 ▲(20.00% Upside)

The score is primarily weighed down by weak financial performance—large ongoing losses, declining revenue, and negative equity with meaningful debt. Technicals also point to a sustained downtrend with weak momentum. Valuation offers limited support given negative earnings and no dividend, while recent corporate events are mixed: liquidity improved via financing, but dilution/regulatory and shareholder constraints remain.

Positive Factors

Solid gross margin (~55%)

A sustained ~55% gross margin indicates the core therapeutic products have favorable unit economics. Over the medium term this supports scalable profitability if SG&A and R&D growth are controlled, and it strengthens the case for margin recovery as revenues stabilize.

Proprietary placental-derived platform

A unique, platform-driven approach creates durable competitive advantages: platform extensibility across oncology, degenerative diseases and longevity enables multiple indications, partnership opportunities, and potential recurring revenue streams from licensing or co-development.

Improved cash burn vs prior years

Material reduction in cash burn versus earlier years shows progress on cost discipline and raises the runway profile. While still negative, lower burn reduces near-term financing frequency and gives management more time to execute commercialization or restructuring initiatives.

Negative Factors

Deep unprofitability and falling revenue

Severe losses and shrinking revenue impair the company’s ability to self-fund growth and extend runway. Persistently negative margins force reliance on external capital, increasing dilution risk and constraining long-term investments in R&D and commercial scale-up.

Weakened balance sheet; negative equity

Negative equity and sizable debt reduce financial flexibility, elevate refinancing risk, and may trigger restrictive covenants. This structural leverage constraint makes funding future trials or commercialization more costly and increases the likelihood of dilutive financings.

Dilutive, investor-favorable financing and governance rights

While the package improves near-term liquidity, investor-favorable terms and governance visibility can limit strategic flexibility, increase potential dilution via conversion/warrants, and prioritize investor upside over long-term shareholder value during future financings.

Celularity Business Overview & Revenue Model

Company Description

Celularity Inc. is a biotechnology company focused on developing innovative cell-based therapies for the treatment of cancer, degenerative diseases, and other serious conditions. The company leverages its proprietary platform that utilizes placental-derived cells, particularly those from the human placenta, to create advanced therapeutic products. Celularity operates primarily within the sectors of regenerative medicine and immunotherapy, aiming to harness the unique properties of these cells to improve patient outcomes.

How the Company Makes Money

Celularity generates revenue through multiple streams, primarily from the commercialization of its cell therapies and related products. This includes sales of its therapeutic offerings directly to healthcare providers and hospitals. Additionally, the company may engage in partnerships with pharmaceutical firms for co-development and licensing of its technologies, which can provide upfront payments, milestone payments, and royalties on future sales. Research grants and funding from governmental and non-governmental organizations focused on advancing regenerative medicine also contribute to their financial resources. Moreover, Celularity may explore collaborations with academic institutions and other biotech companies to enhance its research capabilities and expand its product pipeline, further driving future revenue potential.

Celularity Financial Statement Overview

Summary

Celularity shows strong revenue growth but remains unprofitable with high operational expenses. The balance sheet indicates high leverage and declining equity, raising financial stability concerns. Cash flows are negative but improving, supported by financing activities.

Income Statement

Celularity has shown a significant increase in revenue, growing from $22.8 million in 2023 to $54.2 million in 2024. However, the company remains unprofitable with a negative net profit margin due to high operational expenses, as indicated by negative EBIT and EBITDA margins. The gross profit margin improved to 83.6% in 2024 from 29.7% in 2023, which is a positive sign of operational efficiency.

Balance Sheet

The balance sheet reveals high leverage with a debt-to-equity ratio of 3.29 in 2024, indicating financial risk. The equity ratio is low at 6.7%, showing limited equity buffer. The stockholders' equity has decreased significantly, reflecting potential financial instability and risk.

Cash Flow

Celularity's free cash flow remains negative, but has improved from -$42.7 million in 2023 to -$6.56 million in 2024. The operating cash flow to net income ratio is negative, highlighting ongoing cash drain. However, the company successfully raised funds through financing activities, providing some liquidity cushion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	40.58M	54.22M	22.77M	17.98M	21.34M	14.28M
Gross Profit	22.42M	39.23M	6.75M	-1.69M	11.68M	9.35M
EBITDA	-63.56M	-43.71M	-183.95M	-138.83M	-88.11M	-202.41M
Net Income	-80.64M	-57.89M	-196.29M	14.19M	-100.12M	-208.23M
Balance Sheet
Total Assets	114.24M	132.68M	143.89M	401.07M	414.13M	431.01M
Cash, Cash Equivalents and Short-Term Investments	120.00K	738.00K	227.00K	13.97M	37.24M	54.31M
Total Debt	66.76M	68.84M	65.42M	65.59M	31.14M	30.64M
Total Liabilities	134.33M	123.84M	102.93M	202.16M	314.71M	412.30M
Stockholders Equity	-20.09M	8.84M	40.96M	198.90M	99.42M	18.71M
Cash Flow
Free Cash Flow	-6.61M	-6.56M	-42.73M	-143.11M	-116.30M	-91.03M
Operating Cash Flow	-6.56M	-6.40M	-38.69M	-137.88M	-110.10M	-63.19M
Investing Cash Flow	-1.56M	514.00K	-4.05M	-5.24M	-5.90M	-12.81M
Financing Cash Flow	8.07M	6.70M	24.09M	119.84M	98.56M	102.01M

Celularity Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELU, the sentiment is Negative. The current price of 1.25 is below the 20-day moving average (MA) of 1.28, below the 50-day MA of 1.57, and below the 200-day MA of 2.10, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 42.04 is Neutral, neither overbought nor oversold. The STOCH value of 77.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CELU.

Celularity Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	58 Neutral	$112.08M	-1.52	-49.78%	―	-82.16%	14.58%
STTK	53 Neutral	$299.31M	-4.38	-57.84%	―	-84.46%	33.32%
LTRN	52 Neutral	$39.59M	-2.00	-104.58%	―	―	1.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CELU	44 Neutral	$38.35M	-0.39	―	―	-15.81%	-113.06%
FBLG	44 Neutral	$22.63M	-0.70	-1292.87%	―	―	18.47%
GBIO	39 Underperform	$38.07M	-0.60	-80.81%	―	-17.82%	57.32%

Celularity Corporate Events

Celularity Secures New Financing To Support Strategic Shift

On December 19, 2025, Celularity Inc. entered into senior secured note and convertible note financings with investor Philip A. Barach, receiving $10 million in gross proceeds at closing and structuring commitments for up to an additional $2 million, subject to conditions and the investor’s election. The package comprises a $7 million senior secured term loan backed by a first‑priority lien on substantially all company assets and a secured convertible note facility of up to $5 million, including a $3 million initial note convertible into Class A common stock at $1.66 per share and additional tranches available to both the lead investor and potential participation purchasers, alongside warrants to purchase 3,707,657 shares at $2.00 per share from June 19, 2026 to December 19, 2030. The notes rank pari passu, include investor-favorable participation and “most favored nation” protections for future financings, and grant the investor a board observer right, collectively strengthening Celularity’s near-term liquidity while giving the investor significant economic upside and governance visibility. Management said the December 22, 2025 closing of these privately placed, SEC-registration-exempt securities is intended to support ongoing operations and strategic initiatives as the company sharpens its focus on leveraging its placenta-derived platform in longevity, healthy aging and performance optimization, with implications for a potential reshaping of its portfolio and corporate strategy to drive longer-term value for patients and shareholders.

The most recent analyst rating on (CELU) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Celularity stock, see the CELU Stock Forecast page.

Celularity Shareholders Reject Expansion of Equity Incentive Plan

Celularity Inc. held its Annual Meeting of Stockholders on December 19, 2025, where shareholders voted on director elections, auditor ratification and a proposed amendment to the company’s equity incentive plan. Stockholders reelected three Class I directors to serve until 2028 and ratified the appointment of EisnerAmper LLP as independent auditor for the 2025 fiscal year, but they rejected a proposal to increase the share reserve under the 2021 Equity Incentive Plan by 3.5 million shares, signaling shareholder resistance to further equity-based dilution and potentially constraining the company’s use of stock compensation going forward.

The most recent analyst rating on (CELU) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Celularity stock, see the CELU Stock Forecast page.

Celularity Receives FDA Warning Over Marketing Claims

On December 1, 2025, Celularity Inc. received a warning letter from the FDA concerning the marketing materials for Interfyl, a human connective tissue matrix. The letter emphasized the need to limit outcome-based claims and metabolic activity descriptions in marketing to comply with regulatory standards. Despite the warning, the company’s manufacturing and shipping operations remain unaffected, and no product recalls are required. Celularity is actively engaging with the FDA to address the issues, although there is no assurance of a swift resolution. The company does not anticipate any material impact on its operational or financial expectations due to the letter.

The most recent analyst rating on (CELU) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Celularity stock, see the CELU Stock Forecast page.

Celularity Secures $2 Million in Private Placement

On October 24, 2025, Celularity Inc. entered into a Securities Purchase Agreement with an institutional investor to issue and sell Series A Convertible Preferred Stock and accompanying warrants in a private placement transaction. The initial tranche closed on the same day, providing the company with approximately $2 million in gross proceeds. The funds are intended for working capital and general corporate purposes, potentially impacting the company’s financial flexibility and market operations. The agreement includes provisions for conversion, voting rights, and dividend entitlements, with implications for shareholder equity and market positioning.

The most recent analyst rating on (CELU) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Celularity stock, see the CELU Stock Forecast page.